Trials / Completed
CompletedNCT01363713
A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
A Long-term Open-label Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3 -
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-114 ophthalmic solution |
Timeline
- Primary completion
- 2012-09-01
- First posted
- 2011-06-01
- Last updated
- 2014-10-06
- Results posted
- 2014-09-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01363713. Inclusion in this directory is not an endorsement.